In the study, "Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A," published in The New England Journal of Medicine, researchers used a lentiviral vector to deliver gene ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

Lentiviruses have the unique ability amongst retroviruses of being able to infect non-cycling cells. Vectors derived from lentiviruses have provided a huge advancement in technology and seemingly ...

In the early 1990s, researchers set out to harness viruses for gene therapy applications. The idea was to co-opt a virus’ natural ability to target cells, transverse the membrane and deliver ...

Lentiviral vectors (LVVs) have proven to be extremely versatile genetic delivery vehicles, gaining space as a gene transfer technology tool used both for cell and gene therapies. They are utilised ...

The popularity of viral vector-based gene therapies and vaccines is rapidly growing. However, it is often difficult for scientists to ramp up the generation of these vectors to meet their needs at ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

Figure 1: β-galactosidase expression in mouse liver following lentiviral transduction. We analysed liver toxicity in rodents by measuring the serum alanine aminotransferase (ALT) concentration, a ...

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...